Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease - Endpoints News

Reshma Kewalramani is putting Vertex's $10 billion-plus balance sheet to work. On Wednesday, the biotech announced it would pay $4.9 billion for Alpine Immune Sciences and its experimental drug povetacicept to treat IgA nephropathy, a kidney disease that'Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute